Welcome to our dedicated page for Caribou Biosciences news (Ticker: CRBU), a resource for investors and traders seeking the latest updates and insights on Caribou Biosciences stock.
Caribou Biosciences, Inc. (Nasdaq: CRBU) is a clinical-stage CRISPR genome-editing biopharmaceutical company whose news flow is driven by developments in its allogeneic CAR-T cell therapy programs and related corporate updates. The company focuses on vispacabtagene regedleucel (vispa-cel; formerly CB-010), an allogeneic anti-CD19 CAR-T cell therapy for relapsed or refractory B cell non-Hodgkin lymphoma, and CB-011, an allogeneic anti-BCMA CAR-T cell therapy for relapsed or refractory multiple myeloma.
News about Caribou frequently covers clinical trial milestones, including data readouts from the ANTLER phase 1 trial of vispa-cel and the CaMMouflage phase 1 trial of CB-011. Company press releases have highlighted efficacy and durability data in defined patient cohorts, safety profiles that support outpatient administration for vispa-cel, and dose selection and expansion plans for CB-011 in heavily pretreated multiple myeloma populations.
Investors and followers of CRBU can also expect updates on regulatory interactions and designations, such as RMAT, Fast Track, and Orphan Drug status, as well as communications about planned pivotal trial designs. In addition, Caribou issues quarterly financial results and business updates via press releases and Form 8-K filings, which provide context on its operating runway, research and development spending, and strategic pipeline prioritization.
Another recurring category of news involves conference participation and webcasts, where Caribou’s management and clinical investigators present data at major hematology and oncology meetings and biopharma investor conferences. These events often coincide with new clinical data disclosures or discussions of next steps in trial development.
This news page aggregates such announcements so readers can follow Caribou’s progress in CRISPR-based genome editing, allogeneic CAR-T development, and its lead programs in lymphoma and multiple myeloma. For those tracking CRBU, regular review of this feed helps monitor key clinical, regulatory, and corporate milestones.
Caribou Biosciences (Nasdaq: CRBU) has announced that CEO Rachel Haurwitz will participate in the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, at 8:00 am PT. The event will feature a fireside chat and will be available for live streaming on Caribou's website, with an archived version accessible for 30 days post-event. Caribou is focused on developing advanced CRISPR-based therapies for severe diseases, utilizing its proprietary Cas12a chRDNA technology for precise genome editing.
Caribou Biosciences (Nasdaq: CRBU) will present groundbreaking studies at the 25th Annual Meeting of the American Society for Gene and Cell Therapy (ASGCT) from May 16-19, 2022. The studies demonstrate the superior specificity of Caribou’s chRDNA genome-editing technology in primary human T cells. The presentation, titled 'Conformational control of Cas endonucleases by CRISPR hybrid RNA-DNA guides mitigates off-target activity in T cells', is scheduled for May 16 at 5:30 PM EDT. This innovative technology aims to enhance precision in genome editing, addressing potential off-target effects.
Caribou Biosciences announced the acceptance of an abstract detailing initial clinical data from the ongoing ANTLER Phase 1 trial of CB-010, their lead allogeneic CAR-T cell therapy for patients with relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). The abstract will be presented at the European Hematology Association (EHA) Hybrid Congress in Vienna, Austria, from June 9-12, 2022. CB-010 utilizes advanced CRISPR technology aimed at enhancing antitumor activity.
Caribou Biosciences (CRBU) announced positive preclinical data for its allogeneic CAR-T cell therapy candidate, CB-011, aimed at treating relapsed or refractory multiple myeloma. Data presented at the AACR Annual Meeting show that CB-011 cells are effective against BCMA-positive tumor cells and resist immune rejection. The therapy's unique design includes a proprietary anti-BCMA antibody fragment and an immune cloaking strategy to enhance durability. Caribou plans to submit an IND application in 2022, marking a significant step forward for its CAR-T cell therapy platform.
Caribou Biosciences, Inc. (CRBU) reported significant achievements in 2021, including its successful IPO and the initiation of the ANTLER Phase 1 clinical trial for lead candidate CB-010, aimed at treating r/r B-NHL. The company anticipates submitting an IND application for CB-011 for r/r multiple myeloma in 2022. As of December 31, 2021, Caribou has $413.5 million in cash and securities, supporting its allogeneic CAR-T and CAR-NK pipeline. However, the company reported a net loss of $66.9 million for the year.
Caribou Biosciences (NASDAQ: CRBU) announced preclinical data for its allogeneic anti-BCMA CAR-T cell therapy, CB-011, targeting relapsed or refractory multiple myeloma. The data will be showcased at the AACR Annual Meeting 2022, set for April 8-13, 2022, in New Orleans. CB-011 utilizes Cas12a chRDNA technology to prevent immune rejection, focusing on manufacturing an IND application by 2022. The presentation details include the title, presenter, and time, with registered attendees able to access the content online after April 8. Caribou continues advancing its CRISPR-based therapies.
Caribou Biosciences (Nasdaq: CRBU) announced that CEO Rachel Haurwitz will present at two investor conferences in March 2022. The first event is the Oppenheimer 32nd Annual Healthcare Conference on March 16 at 10:00 am ET. The second is the H.C. Wainwright Gene Therapy and Gene Editing Conference on March 30, with a presentation webcast starting at 7:00 am ET. Webcasts will be available on Caribou's website for 30 days post-event. The company focuses on CRISPR genome editing technology to develop precise therapies for serious diseases.
On February 7, 2022, Caribou Biosciences (Nasdaq:CRBU) announced that its CEO, Rachel Haurwitz, Ph.D., will participate in a fireside chat at the SVB Leerink 11th Annual Global Healthcare Conference on February 17 at 2:20 pm ET. A live webcast will be available on Caribou's website, with an archived version accessible for 30 days post-event.
Caribou specializes in CRISPR genome editing, utilizing advanced technologies, including chRDNAs, for precise gene modifications aimed at developing innovative therapies for serious diseases.
Caribou Biosciences has appointed Dr. Syed Rizvi as chief medical officer, a role aimed at steering its oncology cell therapy pipeline. Dr. Rizvi brings over 20 years of drug development experience, having previously led clinical strategy for CAR-T therapies like ABECMA and BREYANZI. The company plans to disclose initial data from its ANTLER Phase 1 clinical trial for product candidate CB-010 in 2022, file an IND application for CB-011, and select targets for its CAR-NK cell therapy, CB-020. Dr. Rizvi's leadership is anticipated to enhance Caribou’s development efforts.
Caribou Biosciences, Inc. (Nasdaq: CRBU) announced that Rachel Haurwitz, Ph.D., President and CEO, will present a corporate update at the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, at 9:45 am ET. The presentation will be available via live webcast on Caribou's website, with an archived version accessible for 30 days post-event. Caribou is advancing its CRISPR genome-editing technology, focusing on developing next-generation CAR-T and CAR-NK cell therapies to treat severe diseases.